CytoHub

Menu

Process Development

Process Optimization.Critical Parameters. Development with AI.

Process Optimization. Critical Parameters. Development with AI.

At Cytohub, we understand that a robust and optimized process is vital for the successful development of cell and gene therapies. Our Process Development services are tailored to meet the unique requirements of different therapeutic approaches, including iPSC-based, autologous, and allogenic processes. With advanced process analytics, cutting-edge technologies, and the power of BioEngineAI, we empower you to accelerate the translation of innovative therapies from the lab to the clinic.

iPSC-Based Process Development: Unleashing the Potential


In iPSC-based process development, Cytohub offers a comprehensive suite of solutions to maximize the therapeutic potential of induced pluripotent stem cells. Our process development team employs Design of Experiments (DOE) screening, coupled with advanced process analytics, to optimize critical process parameters. We utilize various cell lines, including non-edited iPSCs, edited iPSCs, ES cells, and other relevant cell lines. By leveraging our expertise in suspension culture strategies and utilizing diverse media formulations, we enable scalable and efficient iPSC-based process development.

Autologous Process Development: Pioneering Personalized Therapies

Cytohub specializes in autologous process development, focusing on CAR T cells, NK cells, and HSPCs (Hematopoietic Stem and Progenitor Cells). Our team excels in each step of the autologous process, starting from the collection of blood cells through isolation and washing, transduction/expansion, and cryopreservation. To ensure quality and consistency, we employ our state-of-the-art BioEngineAI analytics platform. Our proprietary BioEngineAI software enables us to analyze critical process parameters such as cell count viability, cytokine production, cell function, and cell phenotype.

Allogenic Process Development: Advancing the Reach of Cell and Gene Therapies

Our allogeneic process development workflow is designed to enhance efficiency and accelerate the translation of your cell and gene therapies from the laboratory to clinical settings. We leverage advanced technologies and state-of-the-art equipment to streamline the manufacturing process, optimizing cell expansion, and ensuring consistent and reliable product quality.
With the integration of BioEngineAI analytics, our allogeneic process development offers unparalleled insights into the complex interactions and dynamics of cell and gene therapies. 

Closed System: Eliminating Contamination and Improving FDA Approval Chances


At Cytohub, we utilize a closed system approach to eliminate the risk of contamination and improve your chances of FDA approval. Our closed systems are designed to minimize the risk of contamination and to facilitate the successful transfer of your cell and gene therapy product from process development to clinical deployment.

Our comprehensive process development strategies, coupled with our proprietary BioEngineAI software, enable us to provide you with unparalleled support throughout your cell and gene therapy development process. We offer customized solutions tailored to your specific product needs and requirements.